Avadel pharmaceuticals to participate in a fireside chat at the 10th annual svb leerink global healthcare conference

Dublin, ireland, feb. 10, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the avadel management team will participate in a fireside chat at the 10th annual svb leerink global healthcare conference, which is being held february 24th to 26th.
AVDL Ratings Summary
AVDL Quant Ranking